Market Cap 362.60B
Revenue (ttm) 61.16B
Net Income (ttm) 4.23B
EPS (ttm) N/A
PE Ratio 20.62
Forward PE 14.12
Profit Margin 6.91%
Debt to Equity Ratio -20.91
Volume 27,982,300
Avg Vol 7,433,216
Day's Range N/A - N/A
Shares Out 1.77B
Stochastic %K 7%
Beta 0.34
Analysts Strong Sell
Price Target $249.82

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 847 932 7900
Address:
1 North Waukegan Road, North Chicago, United States
Guntz
Guntz Mar. 21 at 1:14 PM
$ABBV Fought well yesterday considering the rest of the market. Defended$204 multiple times and large buy orders came in. Hopefully see a nice bounce tomorrow.
1 · Reply
BioTechHealthX
BioTechHealthX Mar. 21 at 4:49 AM
$ABBV AbbVie (NYSE: ABBV) is stepping into the booming obesity drug race with promising early data. Combined with its strong immunology portfolio, this healthcare giant could be entering a powerful new growth phase investors shouldn’t ignore. https://biotechhealthx.com/biotech-news/is-abbvie-abbv-a-great-investment-choice/
0 · Reply
TechTraderGrok
TechTraderGrok Mar. 20 at 9:28 PM
Covered $ABBV at $203.62 (+2.6%). From Grok: "We went short on the breakdown amid competitive pressure but after a solid 4-point gain as it tests February lows around 204 with no further acceleration or major new negatives we're covering to cash." https://www.techtrader.ai/grokwall/?post=17177&utm_source=dlvr.it&utm_medium=stocktwits
0 · Reply
Guntz
Guntz Mar. 20 at 5:26 PM
$ABBV $207ISH break and we could see some short covering from those that shorted last two days.
0 · Reply
67X_ROI_Q1_2026
67X_ROI_Q1_2026 Mar. 20 at 3:50 PM
$SLS @Bcon852 Phase 3 Results / 80th event Could occur at Any Time - it is conceivable, and offers a Slight discount - so possible. -- Pharma's have enough, know enough, Aza+VEN Failed 3 Large Phase 3 Trials, including 2 for AML Remission Maintenance - VIALE-M and VIALE-T both Failed. $ABBV $BMY $RHHBY who conducted the trials, Know Precisely how their Drugs work or don't work for AML Patients IN REMISSION/ they also see the Extended GPS P3 Data, like everyone Else - 54 of 128 Survivors at 2 YEARS - is a miracle for these AML CR2 Transplant Ineligible Patients. - So they May be Willing to Pay Something Reasonably CLose to Angelos 'Max Value' Requirement. -We know SLS is for Sale - we Know there has been buyer interest, we know there are ongoing negotiations and the Last words on the subject from the CEO were " we will let the public know when we have something concrete ". -8k Change of Control GC/CFO options accelerating. - no RSU's - no hiring of commercial team ... and more
0 · Reply
67X_ROI_Q1_2026
67X_ROI_Q1_2026 Mar. 20 at 2:53 PM
$SLS $ABBV $GILD $114M Cash no Debt ... it is not a question of will SLS hit $6 $7 or $10 with the Super Cashed 10-K next week, - its not a question of will $SLS hit a new 52 week high before the close today - we did hit 1 every day Last Week. - it is a Simple Question of Value. What is an immunotherapy that will treat 10's of thousands of AML patients each year worth? 15 Gps treatments year 1 - and 6 each year after, year. Xcco Estimated $280K Rev Y1 Rev Per Patient -- What is Gps worth. 80% Immune Response - Phase 2 MSKCC Results better than Transplant. Confirmed Survival Advantage in every previous trial. Safe. What is Gps worth to Big Pharma? Change of Control 8K Accelerating Options for General Counsel and CFO. And Phase 3 Results worth Literally Tens of Billions of dollars to big pharma are Incoming - they are inevitable. reddit.com/r/sellasLifescience Direct Link to the GPS/009 Webcast
0 · Reply
middleman
middleman Mar. 20 at 2:22 PM
$ABBV nooooooooo
1 · Reply
Guntz
Guntz Mar. 20 at 2:11 PM
$ABBV Dumps with SPY but never recovers with it🤦🏾
0 · Reply
Guntz
Guntz Mar. 20 at 1:42 PM
$ABBV If we can stay green for the next half hour maybe see a relief rally into close.
0 · Reply
67X_ROI_Q1_2026
67X_ROI_Q1_2026 Mar. 20 at 5:27 AM
$SLS $ABBV $GILD How long would you wait for a 10X to 40X Return? and then ask, what about other people? What about Fund Managers? - and then take dilution OFF the TABLE. - throw in a Serious Chance for a Buy Out sweetener - Everyone Knows SLS getting bought. -and then add Insurance, + Upside Free Roll, a DIRECT COMP, for a Secondary Asset with P2B Data better than P1B data that got bought for $5B SLS has Enough news out to be trading at $10 + right now ahead of the Imminently due P3 data. 8K's are there. Change of Control, Cash. The Writing is on the wall, and has been, but Now SLS has the Money, Fund Managers, Know HoDLING Fat Sack of SLS Shares won't be a dirty diaper bag of dilution - $CING is a perfect example - great news, and its $DIAPER w.out Cash - Smart Money Knows, current GPS PH3 REGAL Patients are experiencing extended survival just like all prior Gps trials. BAT Recently Failed 3 Large Phase 3 Trials - including 2 for AML Remission Maintenance.
0 · Reply
Latest News on ABBV
Buy Or Fear AbbVie Stock At $210?

Mar 19, 2026, 9:26 AM EDT - 2 days ago

Buy Or Fear AbbVie Stock At $210?


Best Dividend Kings: March 2026

Mar 19, 2026, 3:27 AM EDT - 2 days ago

Best Dividend Kings: March 2026

ABM ABT ADM ADP AWR BDX BKH


Harbor Health Care ETF Q4 2025 Portfolio Review

Mar 11, 2026, 8:18 AM EDT - 10 days ago

Harbor Health Care ETF Q4 2025 Portfolio Review

ABVX GMAB LLY MASI MEDI MRK RVMD


February Dividends With 4 Raises: 1.6% Up To 14.5%

Mar 3, 2026, 8:14 AM EST - 18 days ago

February Dividends With 4 Raises: 1.6% Up To 14.5%

BMY BTI MA


Best Dividend Aristocrats For March 2026

Feb 27, 2026, 12:21 PM EST - 22 days ago

Best Dividend Aristocrats For March 2026

ABT ADM ADP AFL ALB AMCR AOS


AbbVie Declares Quarterly Dividend

Feb 19, 2026, 9:37 AM EST - 4 weeks ago

AbbVie Declares Quarterly Dividend


AbbVie: Dominating Immunology While Building Oncology Upside

Feb 17, 2026, 1:11 AM EST - 4 weeks ago

AbbVie: Dominating Immunology While Building Oncology Upside


AbbVie sues US health agency over Botox price controls

Feb 11, 2026, 6:49 PM EST - 5 weeks ago

AbbVie sues US health agency over Botox price controls


Abbvie sues US health agency over Botox

Feb 11, 2026, 5:13 PM EST - 5 weeks ago

Abbvie sues US health agency over Botox


2 Urgent Sells And 2 No Brainer Dividend Buys

Feb 11, 2026, 4:06 PM EST - 5 weeks ago

2 Urgent Sells And 2 No Brainer Dividend Buys

AEP AMGN BMY ESS HASI HD PFE


Dividend Kings: No Ideal Buys In February's 57

Feb 10, 2026, 9:45 AM EST - 5 weeks ago

Dividend Kings: No Ideal Buys In February's 57

ABM ADP CWT FRT FTS HRL HTO


AbbVie: The Market Is Getting It Wrong

Feb 5, 2026, 8:52 AM EST - 6 weeks ago

AbbVie: The Market Is Getting It Wrong


AbbVie Inc. (ABBV) Q4 2025 Earnings Call Transcript

Feb 4, 2026, 1:20 PM EST - 6 weeks ago

AbbVie Inc. (ABBV) Q4 2025 Earnings Call Transcript


AbbVie Revenue Rises on Immunology Growth

Feb 4, 2026, 8:34 AM EST - 6 weeks ago

AbbVie Revenue Rises on Immunology Growth


Best Dividend Kings: January 2026

Jan 25, 2026, 10:11 PM EST - 7 weeks ago

Best Dividend Kings: January 2026

ABM ABT ADM ADP AWR BDX BKH


Guntz
Guntz Mar. 21 at 1:14 PM
$ABBV Fought well yesterday considering the rest of the market. Defended$204 multiple times and large buy orders came in. Hopefully see a nice bounce tomorrow.
1 · Reply
BioTechHealthX
BioTechHealthX Mar. 21 at 4:49 AM
$ABBV AbbVie (NYSE: ABBV) is stepping into the booming obesity drug race with promising early data. Combined with its strong immunology portfolio, this healthcare giant could be entering a powerful new growth phase investors shouldn’t ignore. https://biotechhealthx.com/biotech-news/is-abbvie-abbv-a-great-investment-choice/
0 · Reply
TechTraderGrok
TechTraderGrok Mar. 20 at 9:28 PM
Covered $ABBV at $203.62 (+2.6%). From Grok: "We went short on the breakdown amid competitive pressure but after a solid 4-point gain as it tests February lows around 204 with no further acceleration or major new negatives we're covering to cash." https://www.techtrader.ai/grokwall/?post=17177&utm_source=dlvr.it&utm_medium=stocktwits
0 · Reply
Guntz
Guntz Mar. 20 at 5:26 PM
$ABBV $207ISH break and we could see some short covering from those that shorted last two days.
0 · Reply
67X_ROI_Q1_2026
67X_ROI_Q1_2026 Mar. 20 at 3:50 PM
$SLS @Bcon852 Phase 3 Results / 80th event Could occur at Any Time - it is conceivable, and offers a Slight discount - so possible. -- Pharma's have enough, know enough, Aza+VEN Failed 3 Large Phase 3 Trials, including 2 for AML Remission Maintenance - VIALE-M and VIALE-T both Failed. $ABBV $BMY $RHHBY who conducted the trials, Know Precisely how their Drugs work or don't work for AML Patients IN REMISSION/ they also see the Extended GPS P3 Data, like everyone Else - 54 of 128 Survivors at 2 YEARS - is a miracle for these AML CR2 Transplant Ineligible Patients. - So they May be Willing to Pay Something Reasonably CLose to Angelos 'Max Value' Requirement. -We know SLS is for Sale - we Know there has been buyer interest, we know there are ongoing negotiations and the Last words on the subject from the CEO were " we will let the public know when we have something concrete ". -8k Change of Control GC/CFO options accelerating. - no RSU's - no hiring of commercial team ... and more
0 · Reply
67X_ROI_Q1_2026
67X_ROI_Q1_2026 Mar. 20 at 2:53 PM
$SLS $ABBV $GILD $114M Cash no Debt ... it is not a question of will SLS hit $6 $7 or $10 with the Super Cashed 10-K next week, - its not a question of will $SLS hit a new 52 week high before the close today - we did hit 1 every day Last Week. - it is a Simple Question of Value. What is an immunotherapy that will treat 10's of thousands of AML patients each year worth? 15 Gps treatments year 1 - and 6 each year after, year. Xcco Estimated $280K Rev Y1 Rev Per Patient -- What is Gps worth. 80% Immune Response - Phase 2 MSKCC Results better than Transplant. Confirmed Survival Advantage in every previous trial. Safe. What is Gps worth to Big Pharma? Change of Control 8K Accelerating Options for General Counsel and CFO. And Phase 3 Results worth Literally Tens of Billions of dollars to big pharma are Incoming - they are inevitable. reddit.com/r/sellasLifescience Direct Link to the GPS/009 Webcast
0 · Reply
middleman
middleman Mar. 20 at 2:22 PM
$ABBV nooooooooo
1 · Reply
Guntz
Guntz Mar. 20 at 2:11 PM
$ABBV Dumps with SPY but never recovers with it🤦🏾
0 · Reply
Guntz
Guntz Mar. 20 at 1:42 PM
$ABBV If we can stay green for the next half hour maybe see a relief rally into close.
0 · Reply
67X_ROI_Q1_2026
67X_ROI_Q1_2026 Mar. 20 at 5:27 AM
$SLS $ABBV $GILD How long would you wait for a 10X to 40X Return? and then ask, what about other people? What about Fund Managers? - and then take dilution OFF the TABLE. - throw in a Serious Chance for a Buy Out sweetener - Everyone Knows SLS getting bought. -and then add Insurance, + Upside Free Roll, a DIRECT COMP, for a Secondary Asset with P2B Data better than P1B data that got bought for $5B SLS has Enough news out to be trading at $10 + right now ahead of the Imminently due P3 data. 8K's are there. Change of Control, Cash. The Writing is on the wall, and has been, but Now SLS has the Money, Fund Managers, Know HoDLING Fat Sack of SLS Shares won't be a dirty diaper bag of dilution - $CING is a perfect example - great news, and its $DIAPER w.out Cash - Smart Money Knows, current GPS PH3 REGAL Patients are experiencing extended survival just like all prior Gps trials. BAT Recently Failed 3 Large Phase 3 Trials - including 2 for AML Remission Maintenance.
0 · Reply
67X_ROI_Q1_2026
67X_ROI_Q1_2026 Mar. 19 at 8:28 PM
$SLS $ABBV $XBI --- BLA requesting approval to market the product for one or more indications. --- ... CR2/3 first indication ... CR1 ... is 4x 5x the Size and will be included. GPS PH2 MSKCC is better than transplant. rNPV for GPS just in Cr2/3 assumes Positive P3 . . .
0 · Reply
Guntz
Guntz Mar. 19 at 7:29 PM
$ABBV I would be content with not dumping into close. Bar has been lowered lol
0 · Reply
Guntz
Guntz Mar. 19 at 6:23 PM
$ABBV Massive amount of selling still unfortunately
0 · Reply
Czreri1
Czreri1 Mar. 19 at 6:12 PM
$ABBV doesn’t hold $204 we are in bad shape
0 · Reply
middleman
middleman Mar. 19 at 5:24 PM
$ABBV 204 on deck
1 · Reply
Guntz
Guntz Mar. 19 at 5:12 PM
$ABBV Took all day to go green. Lost it all and made new LOD in 10 mins. Too many big sell orders, hopeless until that stops.
0 · Reply
Guntz
Guntz Mar. 19 at 4:11 PM
0 · Reply
Czreri1
Czreri1 Mar. 19 at 4:00 PM
1 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Mar. 19 at 3:34 PM
$ABBV this is cheap here!
0 · Reply
67X_ROI_Q1_2026
67X_ROI_Q1_2026 Mar. 19 at 2:58 PM
$SLS $ABBV $XBI @ezimon - I Love when he says, 'because WE TREAT PATIENTS'...
1 · Reply
middleman
middleman Mar. 19 at 2:39 PM
$ABBV oh lord.. hold the line 🥲
1 · Reply
Guntz
Guntz Mar. 19 at 2:26 PM
$ABBV Hopefully when the market bounces at some point that this will move up too. One can hope lol
0 · Reply